ANDREW YEE to Treatment Outcome
This is a "connection" page, showing publications ANDREW YEE has written about Treatment Outcome.
Connection Strength
0.124
-
Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma. Blood Adv. 2025 Mar 11; 9(5):1163-1170.
Score: 0.076
-
Psychosocial and NF-?B Activity Effects of the Stress Management and Resiliency Training: Relaxation Response Resiliency Program (SMART-3RP) on Patients With MGUS and Smoldering Multiple Myeloma: A Randomized Waitlist Control Trial. Psychooncology. 2025 Jul; 34(7):e70216.
Score: 0.019
-
Phase 1 first-in-human study of MEDI2228, a BCMA-targeted ADC, in patients with relapsed refractory multiple myeloma. Leuk Lymphoma. 2024 Dec; 65(12):1789-1800.
Score: 0.018
-
Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients. Leuk Lymphoma. 2016 09; 57(9):2071-6.
Score: 0.010